EA020167B1 - Solid dosage form having a choleretic effect (variants) - Google Patents

Abstract

The invention relates to the pharmaceutical industry and medicine and can be used in the creation and administration of solid dosage forms having a choleretic effect. The present invention is aimed at creating an effective solid dosage form having a choleretic effect. In the description, two variants of the invention are claimed which solve the problem of interest in that the solid dosage form contains dried bile, mineral substances and a pharmaceutically acceptable carbon-containing additional substance with carbonC isotopes. The invention achieves the technical results of a greater and more rapid therapeutic effect in the treatment of liver and gall bladder diseases without decreasing the duration of said therapeutic effect or increasing the concentration of bile.

Description

FIELD OF THE INVENTION

The invention relates to the field of pharmaceutical industry and medicine and can be used in the creation and use of solid dosage forms with choleretic action.

Background of the Related Art

An important problem of modern medicine is the creation of new drugs for the treatment of diseases of the gastrointestinal tract, the proportion of which from all diseases in the country is growing steadily.

The solution to this problem is to create synthetic drugs or to create drugs that include extracts of plant or animal origin, including dietary supplements. To date, many such preparations have been patented in Russia (see RF patent No. 2445965, published on 03/27/2012, RF patent No. 2442595, published on 02/20/2012, RF patent No. 2423993, published on 06/10/2011, RF patent No. 2287335, published on 11/20/2006 , RF patent No. 2281008, published on 08/10/2006, RF patent 2260440, published on 09/20/2005, etc.).

Studies show that one of the ways to solve this problem is the creation of dosage forms based on bile.

So, it is known choleretic agent Allohol, made in the form of coated tablets containing animal bile, dry garlic extract, nettle extract, activated charcoal and excipients (Mashkovsky M.D. Medicines, vol. 1, M. 2000).

In the application, two variants of the solid dosage form are claimed.

An analogue to each variant of the solid dosage form is a solid dosage form containing bile, described in the method for producing Allochol in the form of tablets (RF patent 2260440, published September 20, 2005). The method describes the technology for the preparation of Allohol tablets, which consists in mixing components, such as bile, plant products: nettle extract, garlic, potato starch, activated carbon, flavoring agents, forming a dosage form by granulation, drying, dusting, while dried garlic is mixed , nettle leaves, polyvinylpyrrolidone (PVP) medium molecular weight and separately prepare a mixture of dry bile with a particle size of 0.6-1.0 mm with aerosil, talc and polyvinylpyrrolidone medium molecular weight m, and thereto are added dry granulate and the mixture is tabletted, moistened with 70% sugar syrup containing 0.35-0.40% PVP middle molecular form a shell with powder dusted basic magnesium carbonate.

From other sources, the following is known about Allochol tablets.

The solid dosage form Allochol, made in the form of a tablet (/ H11p://uar1ks.sot.ia/yigi5/a11os1yu1_og5s11adou5kuu-srr.r11r). has a choleretic effect.

The composition of the tablet includes the main (active) and excipients.

Main substances: dry bile (in terms of anhydrous substance) - 80 mg, dried garlic - 40 mg, nettle leaves - 5 mg, activated carbon - 25 mg.

Excipients: magnesium oxide, potato starch, aerosil, calcium stearate, sugar, povidone, basic magnesium carbonate, titanium dioxide, talc, tropeolin O or tartrazine, beeswax, vaseline oil.

Tablets belong to choleretic drugs.

Tablets are used for the following diseases: chronic hepatitis, cholangitis, cholecystitis, atonic constipation.

The Allochol tablet improves the secretory function of the liver cells, causing a moderate choleretic effect. Stimulates the synthesis of bile acids; increases the osmotic gradient between bile and blood, which leads to increased filtration into the bile capillaries of water and electrolytes; accelerates the flow of bile along the bile ducts, prevents the spread of ascending infection and reduces the intensity of the inflammatory process; reduces the chance of cholesterol precipitation with subsequent formation of stones. The process of cholate formation occurs mainly due to taurocholic and deoxycholic acids entering dry bile. An increase in the output of bile into the intestinal lumen promotes a reflex increase in the secretory and motor activity of the digestive tract, improves emulsification of dietary fats and, in general, digestion processes. Elements of garlic, which are part of the drug, contribute to the inhibition of fermentation in the intestines, reducing flatulence.

The drug is well absorbed in the intestine, quickly entering the hepatoduodenal circulation.

Allochol is used in the treatment of the following diseases: chronic cholecystitis, uncomplicated gallstone disease, gallbladder dyskinesia, postcholicystectomy syndrome, constipation, intestinal hypotension, uncomplicated gallbladder cholesterosis.

The disadvantage of the analogue is the relatively low rate of onset of the therapeutic effect.

In addition, there is an analogue (RF patent 2156087, published September 20, 2000). The patent describes a dietary supplement (BAA) for food, including potassium (4-380 mg / l), magnesium (1-510 mg / l), iron (1-2100 mg / l), zinc (1-1240 mg / l) and additionally 29 different minerals and medicines. IN

- 1 020167 patent claims that the biologically active additive has various medicinal properties. The dietary supplement described in the patent can be made by known technologies in the form of a solid form.

However, in the dietary supplement there is no bile and dietary supplement does not have a choleretic effect.

A known method for the prevention and treatment of pathologies caused by an increased and / or decreased content of physiologically necessary macro- and microelements in the human body, including laboratory analysis of human substrates, the identification of excess and / or deficiency of macro- and microelements and the selection of medicines (RF patent 2238749, published 10/27/2004).

So, with an excess of nickel in the human body, plants are selected:

Aralia Manchurian (root) - 20.0 g;

marsh rosemary (aerial parts) - 20.0 g;

three-leaf watch (sheet) - 40.0 g;

and another 17 plants containing biological nickel antagonists, mainly iron, calcium, magnesium, cobalt, manganese, zinc, copper, with a biological accumulation coefficient above 1.0 and contributing to the neutralization and elimination of nickel from the body.

With an excess of lithium in the human body, plants are selected:

Schisandra chinensis (leaf) - 40.0 g;

May birch (leaf) - 20.0 g;

and 11 more plants containing biological lithium antagonists, mainly iron, sodium, potassium, iodine, with a biological accumulation coefficient above 1.0 and contributing to the neutralization and elimination of lithium from the body.

There is also known a method for the prevention and treatment of pathologies caused by increased or decreased levels of physiologically necessary or potentially toxic macro- and microelements in the human body (RF patent 2263511, published 10.11.2005).

In the method, when there is an excess of macro- and micronutrients in the body, phyto-collections from medicinal plants are used as medicines, which help to neutralize and remove from the body an excess of these macro- or micronutrients and containing the maximum concentration of antagonists of the detected excess macro- or microelements. So, with an excess of aluminum - plants containing the maximum concentration of its antagonists such as iron, boron, silicon, phosphorus, magnesium, calcium; with an excess of cobalt - its antagonists: manganese, iron, nickel. Herbal marshmallow (root), warty birch (leaf) or drooping birch (leaf), three-leafed watch (leaf), and other medicinal plants are included in the phytosport.

In the above two patents, the content of minerals in plants has not been investigated or indicated. It will be indicated below that the amount of mineral substances in a particular plant depends on their content in the soil and on the mineral nutrition of plants and can range from 0.00001 to 0.7% by weight of a dry plant.

In the invention, the authors enrich the solid dosage form on the basis of bile with mineral substances at a content exceeding by one or two orders of magnitude the content of mineral substances in all medicinal plants, including those described in RF patents 2263511 and 2238749.

In the process of conducting research, the effect of small concentrations of mineral substances on the achievement of technical results was verified. It has been established, as will be indicated below, that the mineral substances in the concentrations in which they are found in the studied plants and phytochemicals do not affect the achievement of the technical results indicated in the application.

The authors conducted studies to determine the content of mineral substances in Allohol tablets of various manufacturers (Moskhimpharmpreparat named after N.A.Semashko OJSC, Scientific Production Center Borshchagovsky Chemical and Pharmaceutical Plant).

Mineral substances in tablets are contained in the following elements: garlic, nettle leaves, magnesium oxide, aerosil, calcium stearate, basic magnesium carbonate, titanium dioxide, talc, tropeolin (tartrazine).

The concentration of mineral substances was determined by the atomic absorption method for the determination of sodium, potassium, calcium, magnesium, iron, manganese, copper, zinc, lead, cadmium, cobalt, nickel, and chromium. Clause 1.3.2.1 of the source / Guidance on methods for monitoring the quality and safety of biologically active food additives. - M.: Federal Center for Sanitary Inspection of the Ministry of Health of Russia, 2004, 240 p.

The quantitative composition of minerals in the studied tablets is given in table. 1. No other minerals were found.

In addition, the authors conducted a mineral analysis of various plants, including medicinal plants, and phyto-collections for the content of mineral substances.

Investigated: hops (cones), chamomile (flowers), flea plantain (leaf), shepherd’s bag (aerial part), common dandelion (root and leaf), marshmallow (root), birch (leaf), field horsetail (root) , odorous celery (herb), calendula officinalis (flowers), wormwood (herb), etc.

- 2 020167

The studied plants contain minerals: potassium, calcium, magnesium, iron, manganese, copper, zinc, cobalt, etc. It is established that the content by weight of potassium, calcium, magnesium in plants is high - from 0.0001 to 0.7%. So calcium contains 0.01-0.1%, potassium - 0.003-0.7%, magnesium - 0.00010.01%.

The content by weight of iron, manganese, copper, zinc, cobalt, chromium is low - from 0.00003 to 0.0001%. The molybdenum content is 0.00001%.

The experiments also examined dried nettle leaves and garlic heads.

Nettle and garlic have a mineral content in milligrams per kilogram of dry nettle leaves and dried garlic (mg / kg):

calcium - 110 - 150;

magnesium - 120-130;

sodium - 25 - 27.

No other minerals were found.

The amount of mineral substances in a particular plant depends on the mineral content in the soil and on the mineral nutrition of the plants.

The prototype of the invention is a solid dosage form (yyr: //1s1bpb.gi/gi/81a1/2-agys1e8/30§e1sY), having a choleretic effect, made in the form of a tablet containing dried bile, mineral substances in the following ratio of components in mg / kg:

dried bile - 25 10 ³ - 625 10 ³ ;

sodium - 1550.0 - 105000.0;

calcium - 725.0-41500.0;

magnesium - 1350.0-63150.0.

These features of the prototype coincide with the features of both variants of the invention. The dimension mg / kg indicates the content of an element (in particular, dried bile or sodium) in milligrams per kilogram of solid dosage form (in kilogram of solid dosage form).

The disadvantages of the prototype are the relatively low speed of the onset of the therapeutic effect, insufficiently large therapeutic effect, low stability during the expiration date.

In the invention, the disadvantages of the prototype are eliminated by introducing into the tablet a strictly defined amount of additional mineral substances. Also considered is the option of partial replacement of carbon isotopes ¹² C with carbon isotopes ¹³ C.

SUMMARY OF THE INVENTION

Let us define the terms.

Solid dosage forms are: tablets, powders (including capsules), granules.

Tablets are a solid dosage form (Lp: //1c1bpb.gi/gi/81a1/2-ag11s1e8/33-gé1sy). Tablets are made by compressing drugs. Tablets are of various shapes, in particular in the form of cylinders, balls, flattened balls. Tablets are prescribed for oral administration. In some cases, tablets are used for the preparation of solutions, including injection, as well as for subcutaneous implantation (Esperal).

Powders are a solid dosage form with the property of flowability. In some cases, powders are placed in capsules. Capsules are coatings for metered-dose powdered drugs used internally.

Granules are a solid dosage form in the form of grains (grains) of a round, cylindrical or other shape.

Shelf life - the period during which the solid dosage form retains its properties to the extent that ensures its intended use.

Extract - extract, concentrated extraction of active principle from medicinal raw materials. Depending on the extractant, aqueous, alcoholic, ethereal and other extracts are distinguished. According to the degree of condensation after evaporation, it is a liquid, thick (not more than 20-25% moisture) and dry (up to 5% moisture) extract. The application considers a solid dosage form with a thick or dry extract of medicinal plants.

Bile is a biological fluid produced by the liver. Dried bile may contain up to 25% moisture (0 to 25% moisture).

Starch (С ₆ Н ₁₀ О ₅ ) _p - polysaccharides of amylose and amylopectin, of which alpha-glucose is a monomer. Starch, synthesized by different plants in chloroplasts, under the influence of light during photosynthesis, differs somewhat in the structure of grains, the degree of polymerization of molecules, the structure of polymer chains and physicochemical properties.

Aerosil - colloidal silicon dioxide (81О ₂ ), a light micronized powder with pronounced adsorption properties. Technical name - pyrogenic silicon dioxide.

Magnesium oxide is a chemical compound with the formula MdO, colorless crystals, insoluble in

- 3 020167 water.

Calcium stearate is a mixture of calcium salts of stearic and a mixture of stearic and synthetic fatty acids, obtained by the reaction of neutralization of acids with calcium hydroxide. It is used as a plasticizer. It is described by the empirical formula Сз ₆ Н ₇₀ О4Са.

Magnesium carbonate - magnesium carbonate, MdCO ₃ , magnesium salt of carbonic acid.

Titanium oxide (titanium dioxide, titanium dioxide) T1O ₂ is an amphoteric tetravalent titanium oxide.

Talc - Md ₃ 81 ₄ About ₁₀ (OH) ₂ - crystalline substance. It is a crumbly powder of white (occasionally green) color.

Tropeolin is a coloring matter. It is sodium salt No. 8O ₃ -C ₆ -11 ₄ · Ν: Ν.Ι <.

Tartrazine is a synthetic azo dye. It is described by the formula C ₁₆ H ₉ K ₄ Ka ₃ O ₉ 8 ₂ .

An object of the present invention is to provide an effective solid dosage form having a choleretic effect.

In the description claimed two variants of the invention.

In the first embodiment of the invention, the problem is solved due to the fact that the solid dosage form having a choleretic effect is made in the form of a tablet, contains dried bile, mineral substances in the following ratio of components in mg / kg:

dried bile - 25 1 0 ³ - 625 1 0 ³ ;

sodium - 1550.0 - 105000.0;

potassium - 320.0 - 15300.0;

calcium-725.0-41500.0;

magnesium - 1350.0 - 63150.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt-0.03-5.3;

chromium -0.015 -6.5;

molybdenum - 0.01 - 5.0.

From the prototype, the first embodiment of the invention is distinguished by the following set of features:

potassium - 320.0-15300.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt-0.03 - 5.3;

chromium -0.015 -6.5;

molybdenum - 0.01 - 5.0.

In the second embodiment of the invention, the problem is solved due to the fact that the solid dosage form having a choleretic effect is made in the form of a tablet, contains dried bile, mineral substances in the following ratio of components in mg / kg:

dried bile - 25 1 0 ³ - 625 1 0 ³ ;

sodium-1550.0-105000.0;

potassium - 320.0 - 15300.0;

calcium-725.0-41500.0;

magnesium 1350.0-63150.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt - 0.03 - 5.3;

chromium 0.015-6.5;

molybdenum - 0.01 - 5.0;

and in this case, the solid dosage form contains a pharmaceutically acceptable carbon-containing additional substance with ¹³ C carbon isotopes, and the ratio of ¹³ C carbon isotopes to the total carbon amount (to the total carbon isotopes) in the solid dosage form is from 0.003 to 0.75.

The second embodiment of the invention differs from the prototype in the following set of features:

potassium - 320.0-15300.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt-0.03 - 5.3;

chromium 0.015-6.5;

molybdenum - 0.01 - 5.0,

- 4 020167 and at the same time, the solid dosage form contains a pharmaceutically acceptable carbon-containing additional substance with ¹³ C carbon isotopes, and the ratio of ¹³ C carbon isotopes to total carbon (to total carbon isotopes) in solid dosage form is from 0.003 to 0 , 75.

In the particular case of the implementation of the first and second variants of the invention, the content of mineral substances in solid dosage form can be set in a narrower range of values, mg / kg:

sodium - 1550.0 105000 potassium - 320.0 15300.0 calcium - 725.0 41500.0 magnesium - 1350.0 63150.0 iron - 1.0 135.0 Manganese - 0.3 35.0 cobalt - 0.03 5.3 chrome - 0.015 6.5 molybdenum - 0.01 5.0

In another particular case of the implementation of the first and second variants of the invention, the content of mineral substances in solid dosage form can be set in a narrower range of values, mg / kg:

sodium - 1550.0 90,000 potassium - 320.0 10000.0 calcium - 725.0 30500.0 magnesium - 1350.0 40050.0 iron - 1.0 105.0 Manganese - 0.3 25.0 cobalt - 0.03 4.0 chrome - 0.015 - 5.5 molybdenum - 0.01 - 4.0

In another particular case of the implementation of the first and second variants of the invention, the content of mineral substances in solid dosage form can be set in a narrower range of values, mg / kg:

sodium - 1550.0 60,000 potassium - 320.0 8000.0 calcium - 725.0 25000.0 magnesium - 1350.0 35000.0 iron - 1.0 80.0 Manganese - 0.3 15.0 cobalt - 0.03 2.0 chrome - 0.015 3.5 molybdenum - 0.01 2.0

In another particular case of the implementation of the first and second variants of the invention, the content of mineral substances in solid dosage form can be set in a narrower range of values, mg / kg:

sodium - 1550.0 41000 potassium - 320.0 6500.0 calcium - 725.0 21000.0 magnesium - 1350.0 32000.0 iron - 1.0 70.0 Manganese - 0.3 10.0 cobalt - 0.03 1.0 chrome - 0.015 1.5 molybdenum - 0.01 1.0

- 5 020167

In another particular case of the implementation of the first and second variants of the invention, the content of mineral substances in solid dosage form can be set in a narrower range of values, mg / kg:

sodium - 15050.0 - 90,000 potassium - 1500.0 - 10000.0 calcium - 3555.0 30500.0 magnesium - 7000.0 40050.0 iron - 10.0 105.0 Manganese - 1.0 25.0 cobalt - 0.1 4.0 chrome - 0.15 5.5 molybdenum - 0. 1 4.0

In another particular case of the implementation of the first and second variants of the invention, the content of mineral substances in solid dosage form can be set in a narrower range of values, mg / kg:

sodium - 25050.0 90,000; potassium - 2500.0 10000.0; calcium - 15955.0 30500.0; magnesium - 15000.0 40050.0; iron - 20.0 105.0; Manganese - 1.5 25.0; cobalt - 0.15 4.0; chrome - 0.25 5.5; molybdenum - 0.2 4.0.

In another particular case of the implementation of the first and second variants of the invention, the content of mineral substances in solid dosage form can be set in a narrower range of values, mg / kg:

sodium - 30050.0 90,000 potassium - 3000.0 10000.0 calcium - 16000.0 30500.0 magnesium - 20000.0 40050.0 iron - 30.0 105.0 Manganese - 1.5 25.0 cobalt - 0.19 4.0 chrome - 0.35 5.5 molybdenum - 0.27 4.0

In another particular case of the implementation of the first and second variants of the invention, the content of mineral substances in solid dosage form can be set in a narrower range of values, mg / kg:

sodium - 15050.0 41000 potassium - 1500.0 6500.0 calcium - 3555.0 21000.0 magnesium - 7000.0 32000.0 iron - 10.0 70.0 Manganese - 1.0 10.0 cobalt - 0.1 1.0 chrome - 0.15 1.5

molybdenum - 0. 1

1.0

In another particular case of the implementation of the first and second variants of the invention, the content of mineral substances in solid dosage form can be set in a narrower range of values, mg / kg:

- 6 020167

sodium - 25050.0 41000 potassium - 2500.0 6500.0 calcium - 15955.0 21000.0 magnesium - 15000.0 32000.0 iron - 20.0 70.0 Manganese - 1.5 10.0 cobalt - 0.15 1.0 chrome - 0.25 1.5 molybdenum - 0.2 1.0

In another particular case of the implementation of the first and second variants of the invention, the content of mineral substances in solid dosage form can be set in a narrower range of values, mg / kg:

sodium - 30050.0 - 41000 potassium - 3000.0 - 6500.0 calcium - 16000.0 - 21000.0 magnesium - 20000.0 - 32000.0 iron - 30.0 70.0 Manganese - 1.5 10.0 cobalt - 0.19 1.0 chrome - 0.35 1.5 molybdenum - 0.27 1.0

In the particular case of the implementation of the first and second variants of the invention, the content of bile in solid dosage form can be set in a narrower range of values:

solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, in the following ratio of components in mg / kg:

dried bile - 25 10 ³ - 505 10 ³ .

In another particular case of the implementation of the first and second variants of the invention, the content of bile in solid dosage form can be set in a narrower range of values:

solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, in the following ratio of components in mg / kg:

dried bile - 25 10 ³ - 425 10 ³ .

In another particular case of the implementation of the first and second variants of the invention, the content of bile in solid dosage form can be set in a narrower range of values:

solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, in the following ratio of components in mg / kg:

dried bile - 25 10 ³ - 325 10 ³ .

In another particular case of the implementation of the first and second variants of the invention, the content of bile in solid dosage form can be set in a narrower range of values:

solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, in the following ratio of components in mg / kg:

dried bile - 25 10 ³ - 30010 ³ .

In another particular case of the implementation of the first and second variants of the invention, the content of bile in solid dosage form can be set in a narrower range of values:

solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, in the following ratio of components in mg / kg:

dried bile - 70 10 ³ - 625 1 0 ³ .

In another particular case of the implementation of the first and second variants of the invention, the content of bile in solid dosage form can be set in a narrower range of values:

solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, in the following ratio of components in mg / kg:

dried bile - 150 1 0 ³ - 625 10 ³ .

In another particular case of the implementation of the first and second variants of the invention, the content of bile in solid dosage form can be set in a narrower range of values:

solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, in the following ratio of components in mg / kg:

- 7 020167 dried bile - 180 10 ³ - 625 10 ³ .

In another particular case of the implementation of the first and second variants of the invention, the content of bile in solid dosage form can be set in a narrower range of values:

solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, in the following ratio of components in mg / kg:

dried bile - 70 1 0 ³ - 325 1 0 ³ .

In another particular case of the implementation of the first and second variants of the invention, the content of bile in solid dosage form can be set in a narrower range of values:

solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, in the following ratio of components in mg / kg:

dried bile - 150 1 0 ³ - 325 10 ³ .

In another particular case of the implementation of the first and second variants of the invention, the content of bile in solid dosage form can be set in a narrower range of values:

solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, in the following ratio of components in mg / kg:

dried bile - 180'10 ³ - 325 1 0 ³ .

In another particular case of the implementation of the first and second variants of the invention, the content of bile in solid dosage form can be set in a narrower range of values:

solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, in the following ratio of components in mg / kg:

dried bile - 70 10 ³ - 30010 ³ .

In another particular case of the implementation of the first and second variants of the invention, the content of bile in solid dosage form can be set in a narrower range of values:

solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, in the following ratio of components in mg / kg:

dried bile - 150 1 0 ³ - 3 00'10 ³ .

In another particular case of the implementation of the first and second variants of the invention, the content of bile in solid dosage form can be set in a narrower range of values:

solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, in the following ratio of components in mg / kg:

The narrower ranges of the values of minerals and bile given above can be selected for various groups of patients (children, pregnant women, etc.).

This ensures the achievement of the claimed technical results of the invention: increasing the speed of the onset of the therapeutic effect (reducing the time of onset of the therapeutic effect) while maintaining the duration of action without increasing the concentration of bile in the treatment of diseases of the liver and gall bladder;

an increase in the therapeutic effect while maintaining the duration of action without increasing the concentration of bile in the treatment of diseases of the liver and gall bladder.

It is advisable to increase the carbon content in the tablet to increase the content of activated carbon in the tablet and / or to use a pharmaceutically acceptable carbon-containing additional substance or substances and / or a pharmaceutically acceptable carbon-containing excipient. In this case, the amount of ¹³ C carbon isotopes in solid dosage form can be increased.

Further in the application (to simplify the description and streamlining of terms) bile, dry or dried bile - the main active substance. All other substances in the solid dosage form are pharmaceutically acceptable additional substances.

A pharmaceutically acceptable adjuvant may be:

a pharmaceutically acceptable excipient;

a pharmaceutically acceptable carbonaceous excipient;

a pharmaceutically acceptable carbonaceous adjuvant;

carbon, in particular activated carbon;

medicinal plants, in particular dried garlic, nettle leaves;

metal oxides (in particular magnesium oxide; titanium dioxide);

potato starch;

aerosil;

calcium stearate;

sugar;

povidone;

- 8 020167 magnesium basic carbonate;

talc;

tropeolin O or tartrazine;

beeswax;

petroleum jelly;

minerals (in particular, sodium, calcium), etc.

If the substance is a pharmaceutically unacceptable substance for the solid dosage form in question, then such a substance is not used in the dosage form.

In the particular case of the invention, the solid dosage form having a choleretic effect can be made in the form of a tablet containing dried bile, a pharmaceutically acceptable additional substance with mineral substances, or pharmaceutically acceptable additional substance with mineral substances in the following ratio of components in mg / kg:

dried bile - 25 10 ³ - 625 10 ³ ;

sodium - 1550.0 - 105000.0;

potassium - 320.0-15300.0;

calcium - 725.0 - 41500.0;

magnesium 1350.0-63150.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt-0.03 - 5.3;

chrome - 0.015 - 6.5;

molybdenum - 0.01 - 5.0.

As a pharmaceutically acceptable additional substance can use dry garlic extract, dry nettle extract, activated carbon.

In the particular case of the invention, the solid dosage form having a choleretic effect can be made in the form of a tablet containing dried bile, pharmaceutically acceptable additional substances with mineral substances, in the following ratio of components in mg / kg:

dried bile - 25 1 0 ³ - 625 1 0 ³ ;

pharmaceutically acceptable additional substances - the rest; while the content of mineral substances in solid dosage form (or in pharmaceutically acceptable additional substances), mg / kg:

sodium - 1550.0 - 105000.0;

potassium - 320.0 - 15300.0;

calcium - 725.0 - 41500.0;

magnesium 1350.0-63150.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt - 0.03 - 5.3;

chromium -0.015 -6.5;

molybdenum - 0.01 - 5.0.

In the particular case of the invention, the solid dosage form having a choleretic effect can be made in the form of a tablet containing dried bile, pharmaceutically acceptable additional substances with minerals and a carbon-containing substance or with carbon-containing substances, in the following ratio of components in mg / kg:

pharmaceutically acceptable additional substances - the rest; while the content of mineral substances in solid dosage form (or in pharmaceutically acceptable additional substances), mg / kg:

- 9 020167 sodium - 1550.0 - 105000.0;

potassium - 320.0-15300.0;

calcium - 725.0 - 41500.0;

magnesium - 1350.0-63150.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt - 0.03 - 5.3;

chrome - 0.015 - 6.5;

molybdenum is 0.01 - 5.0, and the total carbon content is 8 10 ³ - 6210 ³ mg / kg.

For the task of the invention, the main active ingredient (or simply the main substance) is bile, dry (dried) in terms of anhydrous substance - 25 · 10 ³ -625 · 10 ³ mg / mg; a pharmaceutically acceptable additional substance may be dried garlic - 10 · 10 ³ 325 · 10 ³ mg / mg; nettle leaves - 1.5 · 10 ³ -62.5 · 10 ³ mg / mg; activated carbon - 2.5 · 10 ³ -45 · 10 ³ mg / mg.

In addition, pharmaceutically acceptable additional substances may include magnesium oxide, potato starch, aerosil, calcium stearate, sugar, povidone, basic magnesium carbonate, titanium dioxide, talc, tropeolin O or tartrazine, beeswax, paraffin oil.

Mineral substances (Fe, Cu, Ζη and others) in solid dosage form are contained in pharmaceutically acceptable oxides, pharmaceutically acceptable salts, for example, succinates, chlorides, carbonates or sulfates, as well as in various pharmaceutically acceptable complex compounds.

Pharmaceutically acceptable additional substances (which include minerals) can be various pharmaceutically acceptable oxides, various pharmaceutically acceptable salts, various pharmaceutically acceptable complex compounds.

In the particular case of the invention, the solid dosage form can be made in such a way that tropeolin and / or tartrazine and / or calcium stearate and / or magnesium carbonate are used as a pharmaceutically acceptable carbon-containing additional substance.

The dimension mg / kg relating to the elements of the solid dosage form means their content (in milligrams) in kilogram of solid dosage form.

A solid dosage form in the form of a tablet may contain a shell. The shell can be made using the following substances: Opadry II white, talc, titanium dioxide, polyvinyl alcohol or other pharmaceutically acceptable substances.

Technical results for all variants of the invention are:

an increase in the speed of the onset of the therapeutic effect (a decrease in the time of the onset of the therapeutic effect) while maintaining the duration of action without increasing the concentration of bile in the treatment of diseases of the liver and gall bladder;

an increase in the therapeutic effect while maintaining the duration of action without increasing the concentration of bile in the treatment of diseases of the liver and gall bladder.

The developed solid dosage form can be used in the treatment of the same diseases for the treatment of which the drug Allohol is used.

An additional technical result may be an increase in the stability of the solid dosage form with bile during the expiration date, which was established experimentally.

Currently, an increase in the speed of the onset of the therapeutic effect is provided by: the dosage of the drug and the time of its exposure;

the introduction into the dosage form of an auxiliary ingredient - an accelerator of the speed of exposure (a special case of a regulator of the speed of exposure);

proactive (preventive) use of the drug.

Here are some examples.

A known dosage form (RF application No. 94015245, published on December 27, 1995), in which a 5-10% solution of hyaluronic acid is used as a regulator of the rate of exposure.

Known pacemaker drug (RF patent No. 2068697, published 10.11.1996), containing green toad poison, chlorobutanodihydrate, sodium chloride and water. To increase the onset of the pacemaker effect (while maintaining the duration of action) provided by the specified poison, up to 95% ethyl alcohol is introduced into the drug. Alcohol due to osmotic phenomena causes pain and local negative reaction, which accelerates the effect of the drug.

Biologically active additives are known which, when introduced together with the active principle, increase the pharmacological activity of therapeutic drugs by optimizing the rate of assimilation of the active principle. So in an antitumor drug (USSR copyright certificate No.

- 10 020167

1683190, published on 04/20/1995) polyvinylpyrrolidone and sorbic acid are additionally introduced. These components increase the antitumor activity of the active principle.

A known method of preventing the development of the disease using the extract of the herb marshmallow medicinal (patent RF2380108, published January 27, 2010).

In the invention, an increase in the speed of the onset of the therapeutic effect is achieved while maintaining the duration of action without increasing the concentration of the active substance, due to the introduction of mineral substances into the solid dosage form.

Below is the well-known information about minerals.

Minerals are subdivided into macro- and microelements.

Macronutrients include calcium, phosphorus, magnesium, potassium, sodium, chlorine and sulfur.

Trace elements: iron, copper, manganese, zinc, cobalt, iodine, fluorine, chromium, molybdenum, vanadium, nickel, strontium, silicon, selenium are recognized as essential for human and animal life.

Macronutrients regulate water-salt metabolism, maintain the osmotic pressure in cells and intercellular fluids, which is necessary for the movement of nutrients and drugs between them. Blood formation processes occur with the participation of iron, copper, manganese, calcium and other mineral substances (elements). Minerals (trace elements) activate the action of enzymes, hormones, participate in all types of metabolism.

Minerals in solid dosage form are found in pharmaceutically acceptable oxides, pharmaceutically acceptable salts, for example, succinates, chlorides, carbonates or sulfates, as well as in various pharmaceutically acceptable complex compounds.

Minerals have an antimicrobial effect by inactivating the enzymes necessary for the functioning of microorganisms. Enzyme inactivation occurs through the interaction of metal ions with sulfhydryl groups of enzymes.

Metals have a pronounced local effect on the mucous membranes. At the concentrations of mineral substances considered in the application, the local action of these substances may be astringent or irritating.

The mechanism of local action of metals is due to their ability to react with tissue proteins. As a result of this interaction, proteins coagulate and form albuminates with metal ions. Moreover, if partial coagulation of proteins occurs only in the surface layers of tissues, an astringent or irritating effect is observed that is reversible.

The studies, when developing this application for the invention, showed that the mineral substances that make up the solid dosage form enhance its therapeutic effect, that is, enhance the therapeutic effect of the use of the active substance.

For all variants of solid dosage forms considered in the invention, the rational ranges of the values of the content of mineral substances are as follows, mg / kg:

sodium - 1550.0 - 105000.0;

potassium - 320.0 - 15300.0;

calcium - 725.0 - 41500.0;

magnesium 1350.0-63150.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt-0.03 - 5.3;

chromium 0.015-6.5;

molybdenum - 0.01 - 5.0.

When developing the invention, it was found that an increase in the speed of the onset of the therapeutic effect, an increase in the therapeutic effect without increasing the concentration of the main active substance (bile) in the solid dosage form, is provided by the introduction of certain minerals (a certain combination of minerals) in a quantity strictly defined for each mineral into the solid dosage form. As a result of the research, a weight range in solid dosage form was established for each mineral.

The use of less than indicated in the range, the amount of mineral substance does not lead to the achievement of technical results. The use of more than indicated in the range, the amount of mineral substance not only does not lead to the achievement of technical results, but, in some cases, worsens the therapeutic effect of the action of bile. It was found that with an increase in the concentration of mineral substances in solid dosage form (above the stated ranges), they suppress the action of bile, i.e. the healing effect of bile disappears.

An additional increase in the speed of the onset of the therapeutic effect, an increase in the therapeutic effect without increasing the concentration of the main active substance in solid dosage form is ensured by the partial replacement in the solid dosage form of carbon isotopes ¹² C with carbon isotopes ¹³ C.

- 11 020167

The list of figures, drawings and other materials.

In FIG. 1 shows the dependence of the change in the volume of bile in samples on time, with a change in the mineral composition in solid dosage forms with a bile content of 267 g / kg.

In FIG. 2 shows the dependence of the change in the volume of bile in the samples on time, with a change in the content of mineral substances in solid dosage forms with a bile content of 25 g / kg.

In FIG. 3 shows the dependence of the change in the volume of bile in samples on time, with a change in the content of mineral substances in solid dosage forms with a bile content of 267 g / kg.

In FIG. 4 shows the dependence of changes in the volume of bile in samples on time, when the content of mineral substances in solid dosage forms with a bile content of 625 g / kg changes.

In FIG. 5 is a diagram of a cavitation reactor for isotopic enrichment of various mixtures.

In FIG. 6 shows a cross section of a cavitation reactor.

In FIG. 7 is a diagram of an isotope enrichment plant.

Information confirming the possibility of carrying out the invention.

The invention is illustrated by the examples below.

Example 1. The method of introducing minerals into water.

Example 2. A method of obtaining a solid dosage form and verification of stability.

Example 3. Tests of solid dosage forms for general toxicity.

Examples 4, 5 and 6 illustrate the choleretic effect of the claimed solid dosage forms.

Example 1. The introduction of mineral substances in solution (in water) was carried out according to the method described in the Guide to methods for monitoring the quality and safety of biologically active food additives. - M.: Federal Center for Sanitary Inspection of the Ministry of Health of Russia, 2004, 240 p.

It should be noted that there are other ways of introducing mineral substances into the solution.

Solutions were prepared from pure metals using pharmaceutically acceptable solvents to ensure storage stability of the solutions.

For in-depth studies, when developing an application for an invention, the concentration of metals in solid dosage form was provided in the following ranges, mg / kg:

sodium - 1550.0 - 105000.0;

potassium - 320.0 - 15300.0;

calcium - 725.0 - 41500.0;

magnesium - 1350.0 - 63150.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt - 0.03 - 5.3;

chrome - 0.015 - 6.5;

molybdenum - 0.01 - 5.0.

In addition, studies have been conducted on the extremely high content of minerals in solid dosage form. These studies will be written below.

The concentration of metals in solutions was controlled by the atomic absorption method for determining the contents of sodium, potassium, calcium, magnesium, iron, manganese, copper, zinc, lead, cadmium, cobalt, nickel, and chromium. Clause 1.3.2.1 of the source / Guidance on methods for monitoring the quality and safety of biologically active food additives. - M.: Federal Center for Sanitary Inspection of the Ministry of Health of Russia, 2004, -240s.

Example 2

The claimed solid dosage form (tablet) is made by compressing a tableted mixture - the main active substance and the pharmaceutically acceptable (s) additional (s) substance (c).

To impart additional properties to the desired shape and weight, pharmaceutically acceptable additional substances, in particular mineral substances, potato starch, aerosil, sugar, as well as a pharmaceutically acceptable excipient, in particular talc, beeswax, vaseline oil, etc. can be added to the tablet.

Excipients affect the rate of release, the rate and completeness of absorption of the main active ingredient and other pharmaceutically acceptable additional substances.

For example, we describe the preparation of one solid dosage form with mineral substances of a given concentration, mg / kg:

- 12 020167 sodium -1550.0;

potassium - 320.0;

calcium - 725.0;

magnesium - 1350.0;

iron -1.0;

Manganese - 0.3;

cobalt-0.03;

chromium 0.015;

molybdenum - 0.01.

8 l of distilled water are poured into a stirred reactor. After that, dried bile - 250 g, is loaded into the reactor, solutions with mineral substances are poured with constant stirring.

Then pharmaceutically acceptable additional substances are added to the solution: activated carbon - 190 g, starch - 57 g. The resulting solution is brought to a volume of 10 l with water, stirred and passed through a filter.

Then carry out the evaporation, molding (pressing) and drying of the solid (solid) dosage form.

The control showed high-quality performance of the solid dosage form.

Similarly, other solid dosage forms with minerals and dried bile, described in the application, were obtained.

Studies of stability (shelf life) showed that the solid dosage forms obtained in this way are stable and retain their initial values for 3.5–4 years.

Thus, it provides increased stability of the solid dosage form over the expiration date.

Example 3. Tests for general toxicity were carried out by intraperitoneal injection of a solution (2 ml) obtained from a solid dosage form based on dried bile and minerals in rats. In solid dosage form, a 75% carbon isotope content of ¹³ C. was provided.

For studies of the concentration of mineral substances in solid dosage form selected, mg / kg:

sodium -105000.0;

potassium - 15300.0;

calcium -41500.0;

magnesium-63150.0;

iron -135.0;

Manganese - 35.0;

cobalt - 5.3;

chrome - 6.5;

Molybdenum - 5.0.

LI ₅₀ is up to 3000 mg / kg, which makes it possible to attribute the claimed solid dosage forms to non-toxic substances.

With prolonged use of a solid dosage form based on dried bile and minerals in rats, no changes in the organs and tissues of the body were detected.

Example 4. Verification of the effectiveness of the claimed solid dosage forms.

The authors conducted studies on the effect of Allohol tablets on bile formation in the liver of animals. The bile-forming function of the liver (with the introduction of Allohol into the stomach and without the introduction of Allohol) was studied in a chronic experiment on dogs. During the experiments, the volume of bile in the samples, the content of taurocholic acid, and the temperature of the liver were measured. In addition, the content of mixtures of various bile acids was evaluated, in particular, mixtures of taurochenodeoxycholic and taurodeoxycholic acids. The studies were carried out jointly with scientists of the Institute of Veterinary Medicine of the National Academy of Agrarian Sciences of Ukraine (Kiev) and according to their methods.

The experimental conditions were as follows. The number of dogs is 25 (of which 15 dogs are the control group not subject to the action of the drug Allohol) weighing from 13 to 17 kg. The catheter is installed in the common bile duct. The design of the catheter allows you to make samples of bile, and outside the experiment ensures the passage of bile into the duodenum. Dogs were fed once a day at 3 p.m. Experimental measurements were performed on hungry dogs from 11 a.m. to 15 p.m. In the experiments, quantitative

- 13 020167 the bile secreted by the liver every 30 minutes for 4 hours of the experiment. The drug Allohol was administered at 10 am orally at the rate of 1 tablet per 3 kg of animal weight (or 0.027 g of dry bile per 1 kg of animal weight).

The effects of the drug Allochol on bile formation in the liver of animals are conveniently evaluated by a change in the volume of bile in the samples.

In FIG. 3 shows the dependence of changes in bile volume in samples on time. The time moment of 0 min is characterized by the fact that Allohol was orally administered to the animal an hour before it. On the ordinate axis - bile content in the sample. The abscissa is time.

Curve 34 (see Fig. 3) is the change in the volume of bile in the control group of animals that did not receive the drug Allohol.

Curve 38 is the change in bile volume (upper bound of values) in animals treated with Allochol.

Curve 40 is the change in the volume of bile (lower bound of values) in animals that received the drug Allohol.

All curves of changes in the volume of bile in animals treated with Allochol pass through region 39 (the shaded region between curves 38 and 40).

A comparison of curves 34, 38 and 40 shows that Allochol stimulates bile formation.

In experiments, an increase in the acid content in bile, in particular, taurocholic acid, was also established (graph 2 in the source Lp: //1c&pd.gi/gi/81a1/2-ag11s1e8/30 -de1sY).

In the experiments, the choleretic effect of only dry (dried) bile was also evaluated (tablets consisted only of dry pressed bile weighing 80 mg). In FIG. 3, the curves of the effect of dry bile on bile formation from time to time pass along curve 34 and through region 39.

In studies, the content of bile and minerals in the preparation was reduced and increased. The mineral composition (quantitative and qualitative) was changed due to changes in the amount of the following elements: garlic, nettle leaves, magnesium oxide, aerosil, calcium stearate, povidone, basic magnesium carbonate, titanium dioxide, talc, tropeolin (tartrazine). This or that element was introduced into a tablet or removed from a tablet.

For example, tablets were formed without silicon and titanium. That is, tablets were made without aerosil, titanium dioxide and talc.

The experiments did not establish the effect of an increase (decrease) in the content of sodium, calcium, magnesium on the dynamics of bile formation. However, the authors' experience with the use of mineral substances to increase the effectiveness of the active substance suggests that an increase in the amount of mineral substances in a dosage form with dried bile can affect its effectiveness.

Given this, the authors conducted studies to increase the number of mineral substances and their quantitative composition in solid dosage form. The aim of the research was to achieve a significant increase in bile formation.

In addition to the minerals already existing in Allochol (sodium, calcium, magnesium), potassium, iron, manganese, zinc, copper, cobalt, chromium, and molybdenum were introduced into the solid dosage form.

In FIG. 1 shows the dependence of the change in the volume of bile in samples on time, with a change in the mineral composition in solid dosage forms with a bile content of 267 g / kg.

Curve 53 is characterized by the content of dried bile (267 g / kg) and the content of minerals, mg / kg:

sodium - 36187.0;

calcium - 18900.0;

magnesium - 27600.0;

potassium - 4817.0;

iron - 56.0.

Curve 54 is characterized by the content of dried bile (267 g / kg) and the content of minerals, mg / kg:

sodium -36187.0;

calcium - 18900.0;

magnesium - 27600.0;

potassium - 4817.0;

iron - 56.0.

Curve 54 differs from curve 53 in that curve 54 reflects the effect of using ¹³ C isotopes on the effectiveness of the solid dosage form. Here, the carbon-13 isotope content was 15% of all carbon (of all carbon isotopes) in the dosage form.

- 14 020167

Curve 55 is characterized by the content of dried bile (267 g / kg) and the content of minerals, mg / kg:

sodium -36187.0;

calcium -18900.0;

magnesium - 27600.0;

potassium - 4817.0;

iron - 56.0;

Manganese - 3.2.

Curve 56 is characterized by the content of dried bile (267 g / kg) and the content of minerals, mg / kg:

sodium -36187.0;

calcium - 18900.0;

magnesium - 27600.0;

potassium - 4817.0;

iron - 56.0;

Manganese - 3.2;

zinc - 48.5.

Curve 57 is characterized by the content of dried bile (267 g / kg) and the content of minerals, mg / kg:

sodium -36187.0;

calcium - 18900.0;

magnesium - 27600.0;

potassium - 4817.0;

iron - 56.0;

Manganese - 3.2;

zinc - 48.5;

copper - 5.0.

Curve 58 is characterized by the content of dried bile (267 g / kg) and the content of minerals, mg / kg:

sodium -36187.0;

calcium -18900.0;

magnesium - 27600.0;

potassium - 4817.0;

iron - 56.0;

Manganese - 3.2;

zinc - 48.5;

copper-5.0;

cobalt-0.31.

Curve 59 is characterized by the content of dried bile (267 g / kg) and the content of minerals, mg / kg:

sodium - 36187.0;

calcium -18900.0;

magnesium - 27600.0;

potassium - 4817.0;

iron - 56.0;

Manganese - 3.2;

zinc - 48.5;

copper - 5.0;

cobalt-0.31;

chromium -0.7;

molybdenum - 0.44.

- 15 020167

Curve 60 is characterized by the content of dried bile (267 g / kg) and the content of minerals, mg / kg:

sodium -36187.0;

calcium -18900.0;

magnesium - 27600.0;

potassium - 4817.0;

iron - 56.0;

Manganese - 3.2;

zinc - 48.5;

copper-5.0;

cobalt-0.31;

chrome 0.7;

molybdenum - 0.44.

Curve 59 differs from curve 60 in that curve 60 reflects the effect of the use of C isotopes on the effectiveness of the solid dosage form. Here, the carbon-13 isotope content was 15% of all carbon (of all carbon isotopes) in the dosage form.

An analysis of the above research results (curves 38.53-60) led to the conclusion that it is advisable to conduct in-depth studies on the use of mineral substances and C isotopes to increase the choleretic effect of solid dosage forms based on dried bile.

Below are the results of in-depth studies on the use of mineral substances and ¹³ C isotopes to increase the choleretic effect of solid dosage forms.

The studied pharmaceutical compositions are given in table. 2-10.

During the work, they were guided by the recommendations given in the source: Guidelines for the experimental (preclinical) study of new pharmacological substances. Edited by R.U. Khabriev. - M.: Ministry of Health of the Russian Federation, 2005.

Below we describe the choleretic effect of the claimed solid dosage forms with a bile content of 25 g / kg.

In FIG. 2 shows the dependence of the change in the volume of bile in the samples on time, with a change in the content of mineral substances in solid dosage forms with a bile content of 25 g / kg.

In experiments it was found that the claimed solid dosage forms based on dried bile and minerals have a pronounced choleretic effect. The experimental results are shown in FIG. 2.

The experimental conditions were similar to the experimental conditions with Allohol:

1) 15 dogs weighing 13 to 17 kg - a control group not exposed to the claimed solid dosage forms;

2) bile-forming (choleretic) function of the liver (with the introduction of the claimed solid dosage forms into the stomach) was investigated in a chronic experiment on dogs. Studies were performed on 6-10 dogs weighing 13 to 17 kg for each of the dosage forms (No. 1-72), that is, for each dosage form, 6-10 experiments were conducted.

Curve 34 (see Fig. 2) is the change in the volume of bile in the control group (15 dogs) of animals that did not receive a choleretic drug (tablets).

Curve 35 is the change in bile volume (upper bound of values) in animals (6-10 dogs) that received a choleretic drug - 0.0027 g of dry bile per 1 kg of animal weight.

Curve 37 is the change in the volume of bile (lower bound of values) in animals that received a choleretic drug - 0.0027 g of dry bile per 1 kg of animal weight.

All curves of changes in the volume of bile in animals treated with a choleretic drug pass through region 36 (the shaded area between curves 35 and 37).

Curve 34 and through region 44 (near the lower boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 2.

Curve 34 and through region 45 (near the lower boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 4.

Curve 34 and through region 46 (near the lower boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 5.

Curves of changes in bile volume in animals treated with choleretic solid drug

- 16 020167 forms with serial number 1, pass significantly below area 44. Solid dosage form No. 1 (see Table 2) practically does not exceed the effect of dry bile in its action. Therefore, this solid dosage form is not practical to use.

Solid dosage form No. 6 (see table. 2) practically does not exceed the effect of solid dosage form No. 5. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 7 (see table. 2) in its effect is equal to the action of solid dosage form No. 2. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 8 (see Table 2) is inferior (but 10-15%) to the action of solid dosage form No. 2. Therefore, it is not advisable to use this solid dosage form in practice.

Curve 34 and through region 44 pass curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number 10 (see table. 3).

Curve 34 and through region 45 are the curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 12.

Curve 34 and through region 46 pass curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number 13.

Curves of changes in the volume of bile in animals treated with choleretic solid dosage forms with serial number 9 pass significantly below area 44. Solid dosage form No. 9 practically does not exceed the effect of dry bile in its action. Therefore, this solid dosage form is not practical to use.

Solid dosage form No. 14 in its effect practically does not exceed the effect of solid dosage form No. 13. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 15 in its effect is equal to the action of solid dosage form No. 10. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 16 is inferior (by 10-15%) to the action of solid dosage form No. 10. Therefore, it is not advisable to use this solid dosage form in practice.

Curve 34 and through region 44 (near the upper boundary of the region and along the upper boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number 18 (see Table 4).

Curve 34 and through region 45 (near the upper boundary of the region and along the upper boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 20.

Curve 34 and through region 46 (near the upper boundary of the region and along the upper boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 21.

Curves of changes in the volume of bile in animals treated with choleretic solid dosage forms with serial number 17 pass significantly below area 44. Solid dosage form No. 17 practically does not exceed the effect of dry bile in its action. Therefore, this solid dosage form is not practical to use.

Solid dosage form No. 22 in its effect practically does not exceed the effect of solid dosage form No. 21. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 23 in its effect is equal to the action of solid dosage form No. 18. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 24 is inferior (by 10-15%) to the action of solid dosage form No. 18. Therefore, it is not advisable to use this solid dosage form in practice.

Example 5. We describe the choleretic effect of the claimed solid dosage forms with a bile content of 267 g / kg.

In FIG. 3 shows the dependence of the change in the volume of bile in samples on time, with a change in the content of mineral substances in solid dosage forms with a bile content of 267 g / kg.

In experiments it was found that the claimed solid dosage forms based on dried bile and minerals have a pronounced choleretic effect. The experimental results are shown in FIG. 3.

Curve 34 (see Fig. 3) is the change in the volume of bile in the control group (15 dogs) of animals that did not receive a choleretic drug (tablets).

Curve 38 is the change in bile volume (upper bound of values) in animals (6-10 dogs), gender

- 17 020167 those who had a choleretic drug - 0.027 g of dry bile per 1 kg of animal weight.

Curve 40 is the change in the volume of bile (the lower bound of the values) in animals that received a choleretic drug - 0.027 g of dry bile per 1 kg of animal weight.

All curves of changes in the volume of bile in animals treated with a choleretic drug pass through region 39 (the shaded region between curves 38 and 40).

Curve 34 and through region 47 (near the lower boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number 26 (see table 5).

Curve 34 and through region 48 (near the lower boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 28.

Curve 34 and through region 49 (near the lower boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 29.

Curves of changes in the volume of bile in animals treated with choleretic solid dosage forms with serial number 25 pass significantly below area 47. Solid dosage form No. 25 practically does not exceed the effect of dry bile in its action. Therefore, this solid dosage form is not practical to use.

Solid dosage form No. 30 in its effect practically does not exceed the effect of solid dosage form No. 29. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 31 in its effect is equal to the action of solid dosage form No. 26. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 32 is inferior (by 10-15%) to the action of solid dosage form No. 26. Therefore, it is not advisable to use this solid dosage form in practice.

Curve 34 and through region 47 pass curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number 34 (see table. 6).

Curve 34 and through region 48 pass curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number 36.

Curve 34 and through region 49 pass curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 37.

Curves of changes in the volume of bile in animals treated with choleretic solid dosage forms with serial number 33 pass significantly below area 47. Solid dosage form No. 33 practically does not exceed the effect of dry bile in its action. Therefore, this solid dosage form is not practical to use.

Solid dosage form No. 38 in its effect practically does not exceed the effect of solid dosage form No. 37. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 39 in its effect is equal to the action of solid dosage form No. 34. Therefore, this solid dosage form is not practical to use.

Solid dosage form No. 40 is inferior (by 10-15%) to the action of solid dosage form No. 34. Therefore, it is not advisable to use this solid dosage form in practice.

Curve 34 and through region 47 (near the upper boundary of the region and along the upper boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 42 (see Table 7).

Curve 34 and through region 48 (near the upper boundary of the region and along the upper boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 44.

Curve 34 and through region 49 (near the upper boundary of the region and along the upper boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 45.

Curves of changes in the volume of bile in animals treated with choleretic solid dosage forms with serial number 41 are significantly lower than area 47. Solid dosage form No. 41 practically does not exceed the effect of dry bile in its action. Therefore, this solid dosage form is not practical to use.

Solid dosage form No. 46 in its effect practically does not exceed the effect of solid dosage form No. 45. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 47 in its effect is equal to the action of solid dosage form No. 42. Therefore, it is not advisable to use this solid dosage form in practice.

- 18 020167

Solid dosage form No. 48 is inferior (by 10-15%) to the action of solid dosage form No. 42. Therefore, it is not advisable to use this solid dosage form in practice.

Example 6. We describe the choleretic effect of the claimed solid dosage forms with a bile content of 625 g / kg.

In FIG. 4 shows the dependence of changes in the volume of bile in samples on time, when the content of mineral substances in solid dosage forms with a bile content of 625 g / kg changes.

In experiments it was found that the claimed solid dosage forms based on dried bile and minerals have a pronounced choleretic effect. The experimental results are shown in FIG. 4.

Curve 34 (see Fig. 4) is the change in bile volume in the control group of animals that did not receive the choleretic drug.

Curve 41 is the change in bile volume (upper bound of values) in animals (6-10 dogs) that received a choleretic drug - 0.063 g of dry bile per 1 kg of animal weight.

Curve 43 is the change in the volume of bile (lower bound of values) in animals that received a choleretic drug - 0.063 g of dry bile per 1 kg of animal weight.

All curves of changes in the volume of bile in animals treated with a choleretic drug pass through region 42 (the shaded region between curves 41 and 43).

Curve 34 and through region 50 (near the lower boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number 50 (see table. 8).

Curve 34 and through region 51 (near the lower boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 52.

Curve 34 and through region 52 (near the lower boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number 53.

Curves of changes in the volume of bile in animals treated with choleretic solid dosage forms with serial number 49 pass significantly below area 50. Solid dosage form No. 49 practically does not exceed the effect of dry bile in its action. Therefore, this solid dosage form is not practical to use.

Solid dosage form No. 54 in its effect practically does not exceed the effect of solid dosage form No. 53. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 55 in its effect is equal to the action of solid dosage form No. 50. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 56 is inferior (by 10-15%) to the action of solid dosage form No. 50. Therefore, it is not advisable to use this solid dosage form in practice.

Curve 34 and through region 50 show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number 58 (see Table 9).

Curve 34 and through region 51 are the curves of changes in the volume of bile in animals receiving choleretic solid dosage forms with serial number No. 60.

Curve 34 and through region 52 pass curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 61.

Curves of changes in the volume of bile in animals treated with choleretic solid dosage forms with serial number 57 pass below area 50. Solid dosage form No. 57 practically does not exceed the effect of dry bile in its action. Therefore, this solid dosage form is not practical to use.

Solid dosage form No. 62 in its effect practically does not exceed the effect of solid dosage form No. 61. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 63 in its effect is equal to the action of solid dosage form No. 58. Therefore, this solid dosage form is not practical to use.

Solid dosage form No. 64 is inferior (by 10-15%) to the action of solid dosage form No. 58. Therefore, it is not advisable to use this solid dosage form in practice.

Curve 34 and through region 50 (near the upper boundary of the region and along the upper boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number 66 (see Table 10).

By curve 34 and through region 51 (near the upper boundary of the region and along the upper boundary of the region)

- 19 020167 undergoes curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number No. 68.

Curve 34 and through region 52 (near the upper boundary of the region and along the upper boundary of the region) show curves of changes in the volume of bile in animals that received choleretic solid dosage forms with serial number 69.

Curves of changes in the volume of bile in animals treated with choleretic solid dosage forms with serial number 65 pass below area 50. Solid dosage form No. 65 practically does not exceed the effect of dry bile in its action. Therefore, this solid dosage form is not practical to use.

Solid dosage form No. 70 in its effect practically does not exceed the effect of solid dosage form No. 69. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 71 in its effect is equal to the action of solid dosage form No. 66. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 72 is inferior (by 10-15%) to the effect of solid dosage form No. 66. Therefore, it is not advisable to use this solid dosage form in practice.

Solid dosage form No. 3 in its choleretic effect occupies an intermediate position between solid dosage forms No. 2 and 4.

Solid dosage form No. 11 in its choleretic action position between solid dosage forms No. 10 and 12.

Solid dosage form No. 19 in its choleretic action, the position between solid dosage forms No. 18 and 20.

Solid dosage form No. 27 in its choleretic effect, the position between solid dosage forms No. 26 and 28.

Solid dosage form No. 35 in its choleretic action, the position between solid dosage forms No. 34 and 36.

Solid dosage form No. 43 in its choleretic action, the position between solid dosage forms No. 42 and 44.

Solid dosage form No. 51 in its choleretic action, the position between solid dosage forms No. 50 and 52.

Solid dosage form No. 59 in its choleretic action, the position between solid dosage forms No. 58 and 60.

Solid dosage form No. 67 in its choleretic effect, the position between solid dosage forms No. 66 and 68.

Experiments have shown that partial replacement of ¹² C carbon isotopes in solid dosage form with ¹³ C carbon isotopes can increase the therapeutic effect of dried bile with minerals in a number of dosage forms by 5% or more.

Numerous experiments have proved that if the dosage form has a choleretic effect, then it is possible, with a high degree of probability, to argue that the dosage form can be successfully used in the treatment of diseases of the liver and gall bladder.

Thus, in practice, it is advisable to use solid dosage forms No. 2-5, 1013, 18-21, 26-29, 34-37, 42-45, 50-53, 58-61, 66-69. A joint analysis of the graphs in FIG. 1-4 allows us to conclude that the use of the claimed solid dosage forms provides an increase in the rate of onset of the therapeutic effect (decrease in the onset of the therapeutic effect) while maintaining the duration of action without increasing the concentration of dried bile. What can be used in the treatment of diseases of the liver and gall bladder.

An increase in the therapeutic effect while maintaining the duration of action without increasing the concentration of dried bile was also confirmed. What can be used in the treatment of diseases of the liver and gall bladder.

Thus, the application is described and technical results are confirmed when using solid dosage forms No. 1 and 2, which can be described as follows.

Solid dosage form No. 1. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, mineral substances in the following ratio of components in mg / kg:

takes takes takes takes takes takes intermediate intermediate intermediate intermediate intermediate intermediate intermediate intermediate

- 20 020167 dried bile - 25 1 0 ³ - 625 1 0 ³ ;

sodium - 1550.0 - 105000.0;

potassium - 320.0-15300.0;

calcium - 725.0 - 41500.0;

magnesium 1350.0-63150.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt - 0.03 - 5.3;

chromium 0.015-6.5;

molybdenum - 0.01 - 5.0.

Solid dosage form No. 2. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, mineral substances in the following ratio of components in mg / kg:

dried bile - 25 10 ³ - 625 10 ³ ;

sodium - 1550.0 - 105000.0;

potassium - 320.0-15300.0;

calcium - 725.0 - 41500.0;

magnesium - 1350.0 - 63150.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt-0.03 - 5.3;

chrome 0.015-6.5;

molybdenum - 0.01 - 5.0, while the solid dosage form contains a pharmaceutically acceptable carbon-containing additional substance with ¹³ C carbon isotopes, and the ratio of ¹³ C carbon isotopes to total carbon (to total carbon isotopes) in solid dosage form is from 0.003 up to 0.75.

Studies of solid dosage form No. 1 with an expanded content of minerals were also conducted.

It was found that in addition to the above mineral substances in solid dosage form No. 1, any of the following mineral substances can be added or added, mg / kg:

zinc 1.0-320.0;

copper -0.1 -21.0.

Moreover, the total content of all components included in the solid dosage form is 1000 g / kg.

Studies of solid dosage form No. 2 with an expanded content of minerals have been carried out.

It has been found that in addition to the above mineral substances in solid dosage form No. 2, any of the following mineral substances may be added or may be added, mg / kg:

zinc 1.0-320.0;

copper - 0.1 -21.0.

Moreover, the total content of all components included in the solid dosage form is 1000 g / kg.

At present, ¹³ C carbon isotopes in the world are widely used in biochemistry and medicine for diagnostics. The application presents the results of our own studies on the effect of carbon ¹³ C isotopes on the effectiveness of solid dosage forms based on dried bile.

It was also found to increase the stability of the claimed solid dosage forms over the shelf life by replacing (from 0.3% to 75%) the carbon isotopes of ¹² C with carbon isotopes of ¹³ C. It was found that carbon isotopes of ¹³ C in the dosage form slow down what is happening in the dosage form reactions form stronger covalent bonds than carbon isotopes ¹² C.

Carbon isotopes ¹³ C increase the resistance of molecules to the oxidative effects of radicals.

- 21 020167

Carbon isotopes ¹³ C are not toxic. The experiments show that feeding mice, rats and guinea pigs with foods enriched with 75% ¹³ C carbon does not lead to side effects and poor health.

In the process of experimental verification of the claimed solid dosage forms enriched in carbon ¹³ C isotopes, it was found that they have increased stability, they are non-toxic and, in addition, have an increased expectorant, local enveloping and anti-inflammatory effect, compared with a solid dosage form in which there are no carbon isotopes ¹³ C.

Methods for the production of a stable highly enriched non-radioactive carbon-13 isotope are widely used in Russian and world industry. Well-developed methods for producing the carbon-13 isotope by gas diffusion through porous septa, vapor diffusion, thermal diffusion, as well as by distillation, isotope exchange, centrifugation, electrolysis, genetic engineering, etc. A brief description of these methods is given in the source / Isotope Separation. Physical Encyclopedia. Air: //b1s.asabet1s.gi/b1s.p8 ^L eps r11ums8 / 1071 / ISOTOPES /.

At the Moscow State Academy of Fine Chemical Technology. M.V. Lomonosov practiced modern nanotechnology for the production and incorporation of atoms of stable carbon isotopes ¹³ C into molecules of various structures. At the academy, they obtain molecules of isotope-labeled compounds with various levels of isotope enrichment - from fractions of a percent to one hundred percent of isotopes in a substance. The work is in the interests of medical diagnosis. In the source / Nanotechnology and the inclusion of 2 13 15 18 atoms of deuterium H, carbon C, nitrogen Ν, and oxygen O in the molecules of amino acids and proteins. Research work: // 5at1 | b.gn / o / o1edt / sbosite18apb8eShpd8o1to81to1bokitep1upapoeypooduyte to Tsiskesheyuto \\ 'bezep] a211g1G.51it1 / 165 links to foreign sources of information from various sources on various sources of information from various sources are given.

In turn, the authors actively participated in the work on the isotopic enrichment of hydrocarbons, as well as reagents for the production of various drugs. The reagents were enriched with ¹³ C carbon isotope (replacing ¹² C carbon isotopes with ¹³ C carbon isotopes) in a cavitation reactor designed by Professor V. I. Kormilitsyn. (Moscow Energy Institute - Technical University).

The reactor was manufactured according to the methodology given in the source / R.F. Ganiev, V.I. Kormilitsyn, L.I. Ukrainsky. Wave technology for the preparation of alternative fuels and the efficiency of their combustion.-M.: Scientific and Publishing Center Regular and chaotic dynamics, 2008.-116 p /. The flow rate in the reactor, along the length of the channel, varied from 10 m / s to 50 m / s.

In FIG. 5 is a diagram cavitation reactor for isotopic enrichment of various mixtures, in particular, the reagents for the preparation of solid dosage forms based on the dried bile enriched with carbon isotope ¹³ C. The reactor is located in a plant which comprises 6NK 6x1-pump, which provides a maximum flow rate of 90 m ³ / h, head 125 m with an electric motor power of 75 kW, a rotational speed of an electric motor rotor and a pump wheel of 2950 rpm. Additionally, the installation contains tanks for reagents and measuring instruments.

The installation diagram is shown in FIG. 7.

The cavitation reactor 1 (see Fig. 5) is made in the form of a flat Laval nozzle with cavitation bodies 2–9 in channel 10.

In FIG. 6 shows a cross section of a cavitation reactor. The reactor channel in the area of cavitation bodies is divided into several channels. For example, cavitation bodies 5 and 6 divide the channel into smaller channels 13, 14 and 15. Outside, the channel is limited by walls 16 and 17, as well as two covers 11 and 12.

In FIG. 5, arrows 18 show the direction of movement of the reagent at the inlet to the reactor, arrow 19 shows the direction of movement of the reagent at the outlet of the reactor.

In the wall 16, channels 24 and 25 are made for supplying carbon dioxide and nitrogen to the cavitation zones.

Installation works as follows. The hydrocarbon reagent from the tank 28 is pumped through the reactor 27 through the pump 27 and enters the tank 28. The pressure drop in the reactor is controlled by pressure gauges 29 and 30. The temperature of the reactant is monitored by thermometer 31. The reagent is heated in the tank by a heater 32.

When the reactor is operating, the hydrocarbon reagent moves along the cavitator channel in direction 18. When flowing around cavitation bodies, the stream is divided into several streams. Beyond the cavitation bodies, cavitation areas arise. In particular, behind the bodies (if you look in the direction of movement of the reagent) cavitation 2, 3, and 4 are cavitation zones 20, 21, 22, and 23. Upon entering the cavitation region, the reagent boils, cavitation bubbles appear, and cavitation bubbles collapse when leaving the cavitation region . At the same time, in the area (in the place) of the collapse of the cavitation bubble, an increase in pressure to several thousand atmospheres and an increase in temperature to a thousand degrees Celsius are observed. Through channels 24 and 25, carbon dioxide is supplied to the stream so that the gas enters the cavitation zone.

The gas-vapor mixture obtained in the reactor, together with the liquid reagent, enters the tank 28. Next, the gas-vapor mixture through pipeline 33 enters the separator with a porous partition, where the vapor

- 22 020167 gas mixtures with ¹³ C and ¹² C are separated.

In the experiments, the reactor worked from several hours to several days. A direct dependence of the degree of enrichment of the vapor-gas mixture and the reagent with the ¹³ C isotope ^{on the} operating time of the cavitation reactor is established.

The amount of ¹³ C carbon isotopes was controlled by high resolution mass spectroscopy.

As a result of the experiments, the reagent was enriched in the ¹³ C carbon isotope from 0.3 to 75%.

Thus, solutions (reagents) were obtained, and solid dosage forms based on dried bile with a content of ¹³ C carbon isotopes from 0.3% to 75% of all carbon in solid dosage form were obtained from solutions.

In the claimed solid dosage forms, the active substance is dried bile. The dried bile content is from 25 · 10 ³ to 625 · 10 ³ mg / kg. Values close to the left border for children and pregnant women. Values close to the right border are for adults and animals.

In the research process, a solid dosage form was created in the form of a tablet with the possibility of separation into parts.

In a formalized form, a tablet, which can be divided into parts, is described as follows.

A solid dosage form made in the form of a tablet contains the active substance and a pharmaceutically acceptable additional substance, and the tablet is made with the possibility of separation into parts to obtain two parts for which the conditions are met:

K = (01+ 02) / 0 = 0.9-1.0;

B = | O1-02 | / O = 0-0.1, where K is an indicator that indicates that when divided, they receive two main parts, and can also receive more than two parts, however, at the same time, two of the received parts are the largest in size

B is an indicator that indicates that during separation two parts are obtained, the weight of which can differ by no more than 10%;

O1 is the weight of the first part of the solid dosage form after separation of the solid dosage form;

- the weight of the second part of the solid dosage form after separation of the solid dosage form;

O is the weight of the solid dosage form before separation.

In addition, work was carried out to create a solid dosage form with the possibility of dividing it into parts and obtaining two parts with different indicators. So, a certain indicator (for example, activated carbon content, mineral content, bile content, etc.) in the first part of the solid dosage form differs from the corresponding indicator in the second part of the solid dosage form.

Another example. A solid dosage form was prepared with the possibility of dividing into parts and obtaining two parts for which the dried bile content in the first part of the solid dosage form differs from the dried bile content in the second part of the solid dosage form by 10%.

A solid dosage form made with the possibility of separation into parts with different indicators is called a hybrid solid dosage form. A solid dosage form made with the possibility of separation, for example, into two parts, was made by pressing two prefabricated half-tablets.

This embodiment of the solid dosage form expands the possibilities of using the dosage form.

In the table. 11 and 12 show some field proven hybrid solid dosage forms.

Hybrid solid dosage forms can be described in various ways. Below are a few formal descriptions of these dosage forms.

1. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, minerals, and a tablet made with the possibility of separation into parts to obtain two parts for which the conditions are met:

K = (01 + 02) / 6 = 0.9-1.0;

B = | 01 - 02 | / 0 = 0-0.1, where K is an indicator that indicates that during the separation they receive two main parts, and can also receive more than two parts, however, at the same time, two of the received parts are the largest in size;

B is an indicator that indicates that during separation two parts are obtained, the weight of which can differ by no more than 10%;

- 23 020167

O1 is the weight of the first part of the solid dosage form after separation of the solid dosage form;

- the weight of the second part of the solid dosage form after separation of the solid dosage form;

O is the weight of the solid dosage form before separation, and the dried bile content in the first part of the solid dosage form is different from the dried bile content in the second part of the solid dosage form.

2. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, minerals, and a tablet made with the possibility of separation into parts to obtain two parts for which the conditions are met:

K = (O1 + 02) / C = 0.9-1.0;

b = 1 σι - 02 | / ο = ο-ο.ι, and the content of dried bile in the first part of the solid dosage form is different from the content of dried bile in the second part of the solid dosage form and the content of components in the first part of the solid dosage form, mg / kg :

dried bile - 25 1 0 ³ ;

sodium-1550.0-105000.0;

potassium - 320.0-15300.0;

calcium - 725.0 - 41500.0;

magnesium - 1350.0-63150.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt -0.03 - 5.3;

chrome - 0.015 - 6.5;

molybdenum - 0.01 - 5.0, and the content of components in the second part of the solid dosage form, mg / kg: dried bile - 625 · 10 ³ ;

sodium - 1550.0 - 105000.0;

potassium - 320.0 - 15300.0;

calcium - 725.0 - 41500.0;

magnesium - 1350.0 - 63150.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt-0.03 - 5.3;

chrome - 0.015 - 6.5;

molybdenum - 0.01 - 5.0.

3. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, minerals, and a tablet made with the possibility of separation into parts to obtain two parts for which the conditions are met:

K = (O1 + 02) / 0 = 0.9-1.0;

B = | O1 - 02 | / 0 = 0-0.1, and the content of dried bile in the first part of the solid dosage form is different from the content of dried bile in the second part of the solid dosage form and the content of components in the first part of the solid dosage form, mg / kg:

- 24 020167 dried bile - 25 10 ³ - 325 10 ³ ;

sodium - 1550.0 - 105000.0;

potassium - 320.0-15300.0;

calcium - 725.0 - 41500.0;

magnesium 1350.0-63150.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt - 0.03 - 5.3;

chromium 0.015-6.5;

molybdenum - 0.01 - 5.0, and the content of components in the second part of the solid dosage form, mg / kg: dried bile - 325.01 · 10 ³ -625 · 10 ³ ;

sodium - 1550.0 - 105000.0;

potassium - 320.0 - 15300.0;

calcium - 725.0 - 41500.0;

magnesium - 1350.0-63150.0;

iron - 1.0 - 135.0;

Manganese - 0.3 - 35.0;

cobalt-0.03 - 5.3;

chromium 0.015-6.5;

molybdenum - 0.01 - 5.0.

4. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, minerals, and a tablet made with the possibility of separation into parts to obtain two parts for which the conditions are met:

K = (01+ 02) / O = 0.9-1.0;

B = | O1-02 | / O = 0-0.1, and the content of the components in the first part of the solid dosage form, mg / kg: dried bile - 25'10 ³ - 625 10 ³ ;

sodium -1550.0;

potassium - 320.0;

calcium - 725.0;

magnesium -1350.0;

iron - 1.0;

Manganese - 0.3;

cobalt -0.03;

chromium - 0.015;

molybdenum-0.01, and the content of the components in the second part of the solid dosage form, mg / kg: dried bile - 25 10 ³ - 625 10 ³ ;

sodium -105000.0;

potassium - 15300.0;

calcium -41500.0;

magnesium -63150.0;

iron -135.0;

manganese -35.0;

cobalt-5.3;

chromium -6.5;

molybdenum -5.0.

5. A solid dosage form having a choleretic effect, made in the form of tablets

- 25 020167 ki containing dried bile, minerals, and a solid dosage form made with the possibility of separation into parts to obtain two parts for which the conditions are met:

K = (O1 + 02) / 0 = 0.9-1.0;

B =] 01 - 02 | / 0 = 0-0.1, while the sodium content in the first part of the solid dosage form is chosen so that it differs from the sodium content in the second part of the solid dosage form.

6. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, mineral substance or minerals, and a solid dosage form made with the possibility of separation into parts to obtain two parts for which the conditions are met:

K = (01 + 02) / O = 0.9-1.0;

B = | O1 - 02 | / 0 = 0-0.1, while the solid dosage form contains sodium, and the sodium content in the first part of the solid dosage form is different from the sodium content in the second part of the solid dosage form;

and / or the solid dosage form contains potassium, and the potassium content in the first part of the solid dosage form is different from the potassium content in the second part of the solid dosage form;

and / or the solid dosage form contains calcium, and the calcium content in the first part of the solid dosage form is different from the calcium content in the second part of the solid dosage form;

and / or the solid dosage form contains magnesium, and the magnesium content in the first part of the solid dosage form is different from the magnesium content in the second part of the solid dosage form;

and / or the solid dosage form contains iron, and the iron content in the first part of the solid dosage form is different from the iron content in the second part of the solid dosage form;

and / or the solid dosage form contains manganese, and the manganese content in the first part of the solid dosage form is different from the manganese content in the second part of the solid dosage form;

and / or the solid dosage form contains zinc, and the zinc content in the first part of the solid dosage form is different from the zinc content in the second part of the solid dosage form;

and / or the solid dosage form contains copper, and the copper content in the first part of the solid dosage form is different from the copper content in the second part of the solid dosage form;

and / or the solid dosage form contains cobalt, and the cobalt content in the first part of the solid dosage form is different from the cobalt content in the second part of the solid dosage form;

and / or the solid dosage form contains chromium, and the chromium content in the first part of the solid dosage form is different from the chromium content in the second part of the solid dosage form;

and / or the solid dosage form contains molybdenum, and the molybdenum content in the first part of the solid dosage form is different from the molybdenum content in the second part of the solid dosage form.

7. A solid dosage form having a choleretic effect, made in the form of a tablet, containing dried bile, a pharmaceutically acceptable carbon-containing additional substance, or pharmaceutically acceptable carbon-containing additional substances, and a solid dosage form made with the possibility of separation into parts to obtain two parts for which the conditions are met :

K = (01 + 02) / 0 = 0.94.0;

B = | O1 - 02 | / 0 = 0-0.1, while the content of ¹³ C carbon isotopes in the first part of the solid dosage form differs from the content of ¹³ C carbon isotopes in the second part of the solid dosage form.

8. A solid dosage form having a choleretic effect, made in the form of a tablet, containing dried bile, a pharmaceutically acceptable carbon-containing additional substance or pharmaceutically acceptable carbon-containing additional substances, a mineral substance or mineral substances, and a solid dosage form made with the possibility of separation into parts to obtain two parts for which the conditions are met:

K = (01 + 02) / 0 = 0.9-1.0;

B = | O1 - 02 | / 0 = 0-0.1, while the solid dosage form contains sodium, and the sodium content in the first part of the solid dosage form is different from the sodium content in the second part of the solid dosage form;

and / or the solid dosage form contains potassium, and the potassium content in the first part of the solid dosage form is different from the potassium content in the second part of the solid dosage form;

- 26 020167 and / or the solid dosage form contains calcium, and the calcium content in the first part of the solid dosage form is different from the calcium content in the second part of the solid dosage form;

and / or the solid dosage form contains magnesium, and the magnesium content in the first part of the solid dosage form is different from the magnesium content in the second part of the solid dosage form;

and / or the solid dosage form contains iron, and the iron content in the first part of the solid dosage form is different from the iron content in the second part of the solid dosage form;

and / or the solid dosage form contains manganese, and the manganese content in the first part of the solid dosage form is different from the manganese content in the second part of the solid dosage form;

and / or the solid dosage form contains zinc, and the zinc content in the first part of the solid dosage form is different from the zinc content in the second part of the solid dosage form;

and / or the solid dosage form contains copper, and the copper content in the first part of the solid dosage form is different from the copper content in the second part of the solid dosage form;

and / or the solid dosage form contains cobalt, and the cobalt content in the first part of the solid dosage form is different from the cobalt content in the second part of the solid dosage form;

and / or the solid dosage form contains chromium, and the chromium content in the first part of the solid dosage form is different from the chromium content in the second part of the solid dosage form;

and / or the solid dosage form contains molybdenum, and the molybdenum content in the first part of the solid dosage form is different from the molybdenum content in the second part of the solid dosage form;

and the content of carbon isotopes ¹³ C in the first part of the solid dosage form is different from the content of carbon isotopes ¹³ C in the second part of the solid dosage form.

9. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, mineral substances, and a solid dosage form made with the possibility of separation into parts to obtain two parts for which the conditions are met:

K = (O1 + 02) / O = 0.9 + 1.0;

B = | O1 - 02 | / 0 = 0 + 0.1, in this case, the solid dosage form contains sodium, and the sodium content in the first part of the solid dosage form is 1.001-10 times higher than the sodium content in the second part of the solid dosage form;

and / or the solid dosage form contains potassium, and the potassium content in the first part of the solid dosage form is 1.00110 times greater than the potassium content in the second part of the solid dosage form;

and / or the solid dosage form contains calcium, and the calcium content in the first part of the solid dosage form is 1.001-10 times higher than the calcium content in the second part of the solid dosage form;

and / or the solid dosage form contains magnesium, and the magnesium content in the first part of the solid dosage form is 1.001-10 times higher than the magnesium content in the second part of the solid dosage form;

and / or the solid dosage form contains iron, and the iron content in the first part of the solid dosage form is 1.00110 times greater than the iron content in the second part of the solid dosage form;

and / or the solid dosage form contains manganese, and the manganese content in the first part of the solid dosage form is 1.001-10 times higher than the manganese content in the second part of the solid dosage form;

and / or the solid dosage form contains zinc, and the zinc content in the first part of the solid dosage form is 1.001-10 times higher than the zinc content in the second part of the solid dosage form;

and / or the solid dosage form contains copper, and the copper content in the first part of the solid dosage form is 1.001-10 times greater than the copper content in the second part of the solid dosage form;

and / or the solid dosage form contains cobalt, and the cobalt content in the first part of the solid dosage form is 1.001-10 times greater than the cobalt content in the second part of the solid dosage form;

and / or the solid dosage form contains chromium, and the chromium content in the first part of the solid dosage form is 10 times greater than the chromium content in the second part of the solid dosage form LOOC;

and / or the solid dosage form contains molybdenum, and the molybdenum content in the first part of the solid dosage form is greater than the molybdenum content in the second part of the solid dosage form

- 27 020167 forms in 1.001-10 times.

10. A solid dosage form having a choleretic effect, made in the form of a tablet, containing dried bile, pharmaceutically acceptable carbon-containing (s) additional substance (s), mineral substances, and a solid dosage form made with the possibility of separation into parts with the receipt of two parts for which the conditions are met:

K = (O1 + 02) / O = 0.9 + 1.0;

B = | O1 - 02 | / 0 = 0 + 0.1, while the solid dosage form contains sodium, and the sodium content in the first part of the solid dosage form is 1.001-10 times higher than the sodium content in the second part of the solid dosage form;

and / or the solid dosage form contains potassium, and the potassium content in the first part of the solid dosage form is 1.00110 times greater than the potassium content in the second part of the solid dosage form;

and / or the solid dosage form contains calcium, and the calcium content in the first part of the solid dosage form is 1.001-10 times higher than the calcium content in the second part of the solid dosage form;

and / or the solid dosage form contains magnesium, and the magnesium content in the first part of the solid dosage form is 1.001-10 times higher than the magnesium content in the second part of the solid dosage form;

and / or the solid dosage form contains iron, and the iron content in the first part of the solid dosage form is 1.00110 times greater than the iron content in the second part of the solid dosage form;

and / or the solid dosage form contains manganese, and the manganese content in the first part of the solid dosage form is 1.001-10 times higher than the manganese content in the second part of the solid dosage form;

and / or the solid dosage form contains zinc, and the zinc content in the first part of the solid dosage form is 1.001-10 times higher than the zinc content in the second part of the solid dosage form;

and / or the solid dosage form contains copper, and the copper content in the first part of the solid dosage form is 1.001-10 times greater than the copper content in the second part of the solid dosage form;

and / or the solid dosage form contains cobalt, and the cobalt content in the first part of the solid dosage form is 1.001-10 times higher than the cobalt content in the second part of the solid dosage form;

and / or the solid dosage form contains chromium, and the chromium content in the first part of the solid dosage form is 1.001-10 times higher than the chromium content in the second part of the solid dosage form;

and / or the solid dosage form contains molybdenum, and the molybdenum content in the first part of the solid dosage form is 1.001-10 times higher than the molybdenum content in the second part of the solid dosage form;

and the content of carbon isotopes ¹³ C in the first part of the solid dosage form is greater than the content of carbon isotopes ¹³ C in the second part of the solid dosage form 1,001-10 times.

11. A solid dosage form having a choleretic effect, made in the form of a tablet, containing dried bile, pharmaceutically acceptable carbon-containing (s) additional substance (s), mineral substances, and a solid dosage form made with the possibility of separation into parts with the receipt of two parts for which the conditions are met:

K = (O1 + 62) / 6 = 0.9-1.0;

B = | O1 - 02 | / O = 0-0.1, while the solid dosage form contains sodium, and the sodium content in the first part of the solid dosage form is 1.001-10 times higher than the sodium content in the second part of the solid dosage form;

and / or the solid dosage form contains potassium, and the potassium content in the first part of the solid dosage form is 1.00110 times greater than the potassium content in the second part of the solid dosage form;

and / or the solid dosage form contains calcium, and the calcium content in the first part of the solid dosage form is 1.001-10 times higher than the calcium content in the second part of the solid dosage form;

and / or the solid dosage form contains magnesium, and the magnesium content in the first part of the solid dosage form is 1.001-10 times higher than the magnesium content in the second part of the solid dosage form;

and / or the solid dosage form contains iron, and the iron content in the first part of the solid

- 28 020167 dosage forms more than the iron content in the second part of the solid dosage form in 1,00110 times;

and / or the solid dosage form contains manganese, and the manganese content in the first part of the solid dosage form is 1.001-10 times higher than the manganese content in the second part of the solid dosage form;

and / or the solid dosage form contains zinc, and the zinc content in the first part of the solid dosage form is 1.001-10 times higher than the zinc content in the second part of the solid dosage form;

and / or the solid dosage form contains copper, and the copper content in the first part of the solid dosage form is 1.001-10 times greater than the copper content in the second part of the solid dosage form;

and / or the solid dosage form contains cobalt, and the cobalt content in the first part of the solid dosage form is 1.001-10 times greater than the cobalt content in the second part of the solid dosage form;

and / or the solid dosage form contains chromium, and the chromium content in the first part of the solid dosage form is 1.001-10 times higher than the chromium content in the second part of the solid dosage form;

and / or the solid dosage form contains molybdenum, and the molybdenum content in the first part of the solid dosage form is 1.001-10 times higher than the molybdenum content in the second part of the solid dosage form;

and the content of carbon isotopes ¹³ C in the first part of the solid dosage form is less than the content of carbon isotopes ¹³ C in the second part of the solid dosage form 1,001-10 times.

12. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, mineral substances, and a solid dosage form made with the possibility of separation into parts to obtain two parts for which the conditions are met:

K = (O1 + 02) / O = 0.9-1.0;

B = | 01 - 02 | / 0 = 0-0.1, while the solid dosage form contains sodium, and the sodium content in the first part of the solid dosage form is 1,001-10 times higher than the sodium content in the second part of the solid dosage form;

and the solid dosage form contains potassium, and the potassium content in the first part of the solid dosage form is less than 1.001-10 times less than the potassium content in the second part of the solid dosage form.

13. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, minerals, and a solid dosage form made with the possibility of separation into parts to obtain two parts for which the conditions are met:

K = (01+ 02) / 0 = 0.9-1.0;

B = | O1-02 | / C = 0-0.1, while the solid dosage form contains sodium, and the sodium content in the first part of the solid dosage form is 1.001-10 times higher than the sodium content in the second part of the solid dosage form;

and the solid dosage form contains calcium, and the calcium content in the first part of the solid dosage form is less than 1.001-10 times lower than the calcium content in the second part of the solid dosage form.

14. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, mineral substances, and a solid dosage form made with the possibility of separation into parts to obtain two parts for which the conditions are met:

K = (O1 + 02) / O = 0.9-1.0;

B = | 01 - 02 | / O = 0-0.1, wherein the solid dosage form contains iron, and the iron content in the first part of the solid dosage form is 1.001-10 times greater than the iron content in the second part of the solid dosage form;

and the solid dosage form contains zinc, and the zinc content in the first part of the solid dosage form is less than 1.001-10 times lower than the zinc content in the second part of the solid dosage form.

15. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, minerals, and a solid dosage form made with the possibility of separation into parts to obtain two parts for which the conditions are met:

K = (O1 + 02) / 0 = 0.9-1.0;

B = | C1 - 02 | / 0 = 0-0.1,

- 29 020167 wherein the solid dosage form contains cobalt, and the cobalt content in the first part of the solid dosage form is 1.001-10 times greater than the cobalt content in the second part of the solid dosage form;

and the solid dosage form contains molybdenum, and the molybdenum content in the first part of the solid dosage form is less than 1.001-10 times lower than the molybdenum content in the second part of the solid dosage form.

Thus, the implementation of the claimed solid dosage forms provides: an increase in the rate of onset of the therapeutic effect (decrease in the onset of the therapeutic effect) while maintaining the duration of action without increasing the concentration of bile in the treatment of diseases of the liver and gall bladder;

an increase in the therapeutic effect while maintaining the duration of action without increasing the concentration of bile in the treatment of diseases of the liver and gall bladder.

Table 1. The mineral composition of Allochol tablets of various manufacturers

Minerals Mineral content (in milligrams) per kilogram of solid dosage form (mg / kg) sodium, mg / kg 41256.0 *) calcium, mg / kg 21340.0 magnesium, mg / kg 31680.0 silicon, mg / kg 159.0 titanium, mg / kg 27.0

*) the average value after studies of Allohol tablets from 26 different packs. The scatter of values ranged from 0.1 to 4%.

Table 2. Solid dosage form with dried bile and minerals

Minerals mg / kg The serial number of the solid dosage form with 25 grams of dried bile and minerals, mg / kg G 2 3 4 5 6 7 8 sodium 1050 1550 10,000 36187 105000 120,000 130 100 140,000 potassium 120 320 1200 4817 15300 17050 19030 20000 calcium 550 725 2300 18900 41500 52500 61350 67000 magnesium 970 1350 10050 27600 63150 75,000 83340 95000 iron 0.3 one 10 56 135 195 231 310 manganese 0.03 0.3 one 3.2 35 55 73.8 95 zinc copper cobalt 0.01 0.03 0.1 0.31 5.3 9.5 11.25 14 chromium 0.008 0.015 0.5 0.7 6.5 9.7 11.59 fifteen molyb den 0.007 0.01 0.1 0.44 5 8.5 14.45 nineteen

*) the numbering of solid dosage forms is through.

- 30 020167

Table 3. A solid dosage form with dried bile, minerals and a ratio of ¹³ C carbon isotopes to the total amount of carbon (carbon isotopes) in solid dosage form is 0.003

Minerals mg / kg The serial number of the solid dosage form with 25 grams of dried bile and minerals, mg / kg nine 10 AND 12 thirteen 14 fifteen sixteen sodium 1050 1550 10,000 36187 105000 120,000 130 100 140,000 potassium 120 320 1200 4817 15300 17050 19030 20000 calcium 550 725 2300 18900 41500 52500 61350 67000 magnesium 970 1350 10050 27600 63150 75,000 83340 95000 iron 0.3 one 10 56 135 195 231 310 manganese 0.03 0.3 one 3.2 35 55 73.8 95 zinc copper cobalt 0.01 0.03 0.1 0.31 5.3 9.5 11.25 14 chromium 0.008 0.015 0.5 0.7 6.5 9.7 11.59 fifteen molyb den 0.007 0.01 0.1 0.44 5 8.5 14.45 nineteen

Table 4. A solid dosage form with dried bile, minerals and a ratio of ¹³ C carbon isotopes to the total amount of carbon (carbon isotopes) in solid dosage form is 0.75

Minerals mg / kg The serial number of the solid dosage form with 25 grams of dried bile and minerals, mg / kg 17 eighteen nineteen twenty 21 22 23 24 sodium 1050 1550 10,000 36187 105000 120,000 130 100 140,000 potassium 120 320 1200 4817 15300 17050 19030 20000 calcium 550 725 2300 18900 41500 52500 61350 67000 magnesium 970 1350 10050 27600 63150 75,000 83340 95000 iron 0.3 one 10 56 135 195 231 310 manganese 0.03 0.3 one 3.2 35 55 73.8 95 zinc copper cobalt 0.01 0.03 0.1 0.31 5.3 9.5 11.25 14 chromium 0.008 0.015 0.5 0.7 6.5 9.7 11.59 fifteen molybdenum 0.007 0.01 0.1 0.44 5 8.5 14.45 nineteen

Table 5. Solid dosage form with dried bile and minerals

Minerals mg / kg The serial number of the solid dosage form with 267 grams of dried bile and minerals, mg / kg 25 26 27 28 29th thirty 31 32 sodium 1050 1550 10,000 36187 105000 120,000 130 100 140,000 potassium 120 320 1200 4817 15300 17050 19030 20000 calcium 550 725 2300 18900 41500 52500 61350 67000 magnesium 970 1350 10050 27600 63150 75,000 83340 95000 iron 0.3 one 10 56 135 195 231 310 manganese 0.03 0.3 one 3.2 35 55 73.8 95 zinc copper cobalt 0.01 0.03 0.1 0.31 5.3 9.5 11.25 14 chromium 0.008 0.015 0.5 0.7 6.5 9.7 11.59 fifteen molyb den 0.007 0.01 0.1 0.44 5 8.5 14.45 nineteen

- 31 020167

Table 6. A solid dosage form with dried bile, minerals, and a ratio of ¹³ C carbon isotopes to total carbon (carbon isotopes) in solid dosage form is 0.003

Minerals mg / kg The serial number of the solid dosage form with 267 grams of dried bile and minerals, mg / kg 33 34 35 36 37 38 39 40 sodium 1050 1550 10,000 36187 105000 120,000 130 100 140,000 potassium 120 320 1200 4817 15300 17050 19030 20000 calcium 550 725 2300 18900 41500 52500 61350 67000 magnesium 970 1350 10050 27600 63150 75,000 83340 95000 iron 0.3 one 10 56 135 195 231 310 manganese 0.03 0.3 one 3.2 35 55 73.8 95 zinc copper cobalt 0.01 0.03 0.1 0.31 5.3 9.5 11.25 14 chromium 0.008 0.015 0.5 0.7 6.5 9.7 11.59 fifteen molyb den 0.007 0.01 0.1 0.44 5 8.5 14.45 nineteen

Table 7. A solid dosage form with dried bile, minerals and a ratio of ¹³ C carbon isotopes to the total carbon (carbon isotopes) in solid dosage form is 0.75

Minerals mg / kg The serial number of the solid dosage form with 267 grams of dried bile and minerals, mg / kg 41 42 43 44 45 46 47 48 sodium 1050 1550 10,000 36187 105000 120,000 130 100 140,000 potassium 120 320 1200 4817 15300 17050 19030 20000 calcium 550 725 2300 18900 41500 52500 61350 67000 magnesium 970 1350 10050 27600 63150 75,000 83340 95000 iron 0.3 one 10 56 135 195 231 310 manganese 0.03 0.3 one 3.2 35 55 73.8 95 zinc copper cobalt 0.01 0.03 0.1 0.31 5.3 9.5 11.25 14 chromium 0.008 0.015 0.5 0.7 6.5 9.7 11.59 fifteen molyb den 0.007 0.01 0.1 0.44 5 8.5 14.45 nineteen

- 32 020167

Table 8 Solid dosage form with dried bile and minerals

Minerals mg / kg The serial number of the solid dosage form with 625 grams of dried bile and minerals, mg / kg 49 fifty 51 52 53 54 55 56 sodium 1050 1550 10,000 36187 105000 120,000 130 100 140,000 potassium 120 320 1200 4817 15300 17050 19030 20000 calcium 550 725 2300 18900 41500 52500 61350 67000 magnesium 970 1350 10050 27600 63150 75,000 83340 95000 iron 0.3 one 10 56 135 195 231 310 manganese 0.03 0.3 one 3.2 35 55 73.8 95 zinc copper cobalt 0.01 0.03 0.1 0.31 5.3 9.5 11.25 14 chromium 0.008 0.015 0.5 0.7 6.5 9.7 11.59 fifteen molyb den 0.007 0.01 0.1 0.44 5 8.5 14.45 nineteen

Table 9. A solid dosage form with dried bile, minerals and a ratio of ¹³ C carbon isotopes to the total amount of carbon (carbon isotopes) in solid dosage form is 0.003

Minerals mg / kg The serial number of the solid dosage form with 625 grams of dried bile and minerals, mg / kg 57 58 59 60 61 62 63 64 sodium 1050 1550 10,000 36187 105000 120,000 130 100 140,000 potassium 120 320 1200 4817 15300 17050 19030 20000 calcium 550 725 2300 18900 41500 52500 61350 67000 magnesium 970 1350 10050 27600 63150 75,000 83340 95000 iron 0.3 one 10 56 135 195 231 310 manganese 0.03 0.3 one 3.2 35 55 73.8 95 zinc copper cobalt 0.01 0.03 0.1 0.31 5.3 9.5 11.25 14 chromium 0.008 0.015 0.5 0.7 6.5 9.7 11.59 fifteen molyb den 0.007 0.01 0.1 0.44 5 8.5 14.45 nineteen

- 33 020167

Table 10. A solid dosage form with dried bile, minerals and a ratio of ¹³ C carbon isotopes to the total carbon (carbon isotopes) in solid dosage form is 0.75

Mine mg / kg The serial number of the solid dosage form with 625 grams of dried bile and minerals, mg / kg 65 66 67 68 69 70 71 72 sodium 1050 1550 10,000 36187 105000 120,000 130 100 140,000 potassium 120 320 1200 4817 15300 17050 19030 20000 calcium 550 725 2300 18900 41500 52500 61350 67000 magnesium 970 1350 10050 27600 63150 75,000 83340 95000 iron 0.3 one 10 56 135 195 231 310 manganese 0.03 0.3 one 3.2 35 55 73.8 95 zinc copper cobalt 0.01 0.03 0.1 0.31 5.3 9.5 11.25 14 chromium 0.008 0.015 0.5 0.7 6.5 9.7 11.59 fifteen molyb den 0.007 0.01 0.1 0.44 5 8.5 14.45 nineteen

Table 11. Hybrid (with the possibility of separation into two parts) solid dosage form with dried bile, minerals and carbon isotopes ¹³ C Components Serial number of the hybrid solid dosage form

solid dosage form, mg / kg G1 G2 GZ G4 G1-1 G1-2 G2-1 G2-2 GZ-1 GZ-2 G4-1 G4-2 dried 2510 ³ 25 10 ³ 625 10 ³ 625 10 ³ 2510 ³ 62510 ³ 25 10 ³ 35 10 ³ bile sodium 1550 105000 1550 105000 1550 105000 1550 100,000 potassium 320 15300 320 15300 320 15300 320 15,000 calcium 725 41500 725 41500 725 41500 725 40500 magnesium 1350 63150 1350 63150 1350 63150 1350 62050 iron one 135 one 135 one 135 one 125 manganese 0.3 35 0.3 35 0.3 35 0.3 25 zinc copper cobalt 0.03 5.3 0.03 5.3 0.03 5.3 0.03 5.0 chromium 0.015 6.5 0.015 6.5 0.015 6.5 0.015 6.0 molybdenum 0.01 5 0.01 5 0.01 5 0.01 5.9 ¹³ C,% 75 75 fifty 75 75 75 75 10

Note: G1 - serial number of the hybrid solid dosage form; G1-1 - serial number of the first part of the hybrid solid dosage form; G1-2 - serial number of the second part of the hybrid solid dosage form.

- 34 020167

Table 12 Hybrid (with the possibility of separation into two parts) solid dosage form with dried bile, minerals and carbon isotopes ¹³ C

Components of the solid dosage form, mg / kg Hybrid Solid Dosage Form Number G5 GB G7 G8 G5-1 G5-2 G6-1 G6-2 G7-1 G7-2 G8-1 G8-2 dried bile 2510 ³ 2510 ³ 625 10 ³ 625 10 ³ 625 10 ³ 62510 ³ 85 10 ³ 3510 ³ sodium 1550 1555 104200 105000 1550 1650 1550 100,000 potassium 320 330 15,000 15300 320 360 320 15,000 calcium 725 735 41000 41500 725 825 725 40500 magnesium 1350 1370 63100 63150 1350 1550 1350 62050 iron one 10.6 130 135 one 1.9 one 125 manganese 0.3 0.9 thirty 35 0.3 0.8 0.3 25 zinc copper cobalt 0.03 0. 3 5.0 5.3 0.03 0.3 0.03 5.0 chromium 0.015 0. 15 6.0 6.5 0.015 0.15 0.015 6.0 molybdenum 0.01 0.1 4.5 5 0.01 0.1 0.01 5.9 ¹³ C,% 75 70 55 75 55 75 fifteen 10

CLAIM

Claims (2)

CLAIM 1. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, mineral substances in the following ratio of components in mg / kg: dried bile - 25 1 0 ³ - 625 1 0 ³ ; sodium - 1550.0 - 105000.0; potassium - 320.0 - 15300.0; calcium -725.0 -41500.0; magnesium - 1350.0-63150.0; iron - 1.0 - 135.0; Manganese - 0.3 - 35.0; cobalt-0.03 -5.3; chromium -0.015 -6.5; molybdenum - 0.01 - 5.0. 2. A solid dosage form having a choleretic effect, made in the form of a tablet containing dried bile, mineral substances in the following ratio of components in mg / kg: dried bile - 25 1 0 ³ - 625 1 0 ³ ; sodium - 1550.0 - 105000.0; potassium - 320.0-15300.0; calcium - 725.0 - 41500.0; magnesium - 1350.0-63150.0; iron - 1.0-135.0; Manganese - 0.3 - 35.0; cobalt-0.03 -5.3; chromium -0.015 -6.5; molybdenum is 0.01 - 5.0, and the solid dosage form contains ¹³ C carbon isotopes, and the ratio of ¹³ C carbon isotopes to the total carbon in the solid dosage form is from 0.003 to 0.75.